The closing bell. Bloomberg's comprehensive cross-platform coverage of the U.S. market close starts right now. We are about 2 minutes away from the end of the trading day on this Tuesday.Scarlet Fu and Katie Greifeld here with you to take you through the closing bell. We've got a global simulcast. We're joined now by Carol Massar and tim stanwick bring together our bloomberg television, radio and you tube audiences worldwide as we pass through the most crucial moments of this trading day.And Carol, i feel l ...

[Música] El enamoramiento es una basura y tú no tienes acceso a la realidad. Gracias. Eh, tengo un objetivo muy específico con esta plática. Para empezar, para mí hablar 18 minutos, los que me conocen saben que es un reto importante. Mis talleres duran 40 horas. Eh, pero tengo dos objetivos importantes. Primero, soy un obsesivo del comportamiento humano, de las relaciones humanas. Esto me ha llevado 20 años de mi vida. Eh, quiero compartirles la mayor cantidad de verdades que me he encontrado siendo terapeu ...

I am looking into $STONKS 🔥I was one of the first on X to spot it — real utility, real vision. You can literally buy real stocks with a memecoin lmao!!! That’s insane 🤯.15 years ago, I needed 27 different apps just to buy a Facebook share — now it's one click, on-chain.Bringing #NASDAQ on-chain is the new meta. The team locked 81% of the supply — that’s conviction.I think this might have potential to go to $500M.CA: 27U6sAYSDUJLpeCTTL5gW2wSwLGNRZRZKWJEqTWGbonk ...

LONDON, July 18, 2025 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, announced that it received a notice from The Nasdaq Stock Market LLC ("Nasdaq") dated July 14, 2025, notifying the Company that it is not in compliance with the minimum bid price requirement as set forth under NASDAQ Listing Rule 5550(a)(2)(the "Minimum Bid Price Rule") for continued list ...

Core Insights - Clearside Biomedical, Inc. is exploring a range of strategic alternatives to enhance its SCS platform and drug development pipeline, aiming to maximize stockholder value [1][2][3] - The company has retained Piper Sandler to assist in the strategic evaluation process, considering options such as asset sales, licensing, collaborations, and mergers [1][2] - Clearside's SCS Microinjector is a validated delivery platform for therapies targeting serious retinal diseases, with five commercial and late-stage development collaborations [1][4][10] Company Highlights - The SCS Microinjector enables a non-surgical, repeatable procedure for targeted delivery of therapies to the macula, retina, and choroid, potentially preserving and improving vision in patients with sight-threatening eye diseases [4][10] - Clearside's lead program, CLS-AX, is in development for the treatment of wet age-related macular degeneration (AMD) and has shown positive Phase 2b clinical data [2][8][10] - The company has successfully navigated the FDA regulatory pathway for its first product, XIPERE, which is approved for suprachoroidal use [8][10] Internal Pipeline - CLS-AX is a proprietary axitinib injectable suspension being developed for wet AMD, with a Phase 3 program planned to maximize its commercial potential [8][10] - The company is also evaluating small molecules for treating geographic atrophy (GA) and diabetic macular edema (DME), addressing high unmet medical needs in retinal diseases [8][10] External Collaborations - Clearside has established partnerships with various companies utilizing its SCS injection platform for other ophthalmic therapeutic innovations, including gene therapies and anti-tumor agents [10][13]

Core Viewpoint - The content emphasizes the importance of conducting personal due diligence and consulting competent advisors before making any financial decisions, particularly in the context of investments and trading activities [1]. Group 1 - The website provides general news and publications, personal analysis, and third-party content intended for educational and research purposes [1]. - It explicitly states that the information does not constitute any recommendation or advice for investment actions [1]. - Users are advised to perform their own research and consider their financial situation before making decisions [1]. Group 2 - The website includes information about complex financial instruments such as cryptocurrencies and contracts for difference (CFDs), which carry a high risk of losing money [1]. - It encourages users to understand how these instruments work and the associated risks before investing [1].

SARASOTA, Fla., July 16, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company developing intranasal therapeutics for brain-related conditions, today announced it has entered into a manufacturing agreement with Sterling Pharma Solutions, an industry leading CDMO with multiple US-based development and manufacturing facilities. Oragenics has partnered with Sterling Pharma Solutions for the GMP production of its lead drug candidate, ONP-002, for the treatment of concussion. Th ...

Join us now. Sylvia Jablonsky, Defiance ETF CEO uh and chief me chief investment officer. I I'm I'm feeling I'm feeling you have not been that negative.No. Throughout all this, I I can remember I it's sad because I look at some people and I remember how wrong they were. Yeah.And we have a lot of people on that when I look at now that's all I can think about and I'm not sure why they're here. Glad I'm glad I'm not one of them for You're not one of them. You are not one of them.Why didn't you Um it wasn't a h ...

Core Viewpoint - The content emphasizes the importance of conducting personal due diligence and consulting competent advisors before making any financial decisions, particularly in the context of investments and trading [1]. Group 1 - The website provides general news, publications, and personal analysis intended for educational and research purposes [1]. - It explicitly states that the information does not constitute any recommendation or advice for investment actions [1]. - Users are advised to consider their financial situation and needs before relying on the information provided [1]. Group 2 - The website includes information about complex financial instruments such as cryptocurrencies and contracts for difference (CFDs), which carry a high risk of losing money [1]. - It encourages users to perform their own research and understand the risks involved before making investment decisions [1].

Core Viewpoint - The content emphasizes the importance of conducting personal due diligence and consulting competent advisors before making any financial decisions, particularly in the context of investments and trading activities [1]. Group 1 - The website provides general news, publications, and personal analysis intended for educational and research purposes [1]. - It explicitly states that the information does not constitute any recommendation or advice for investment actions [1]. - Users are advised to perform their own research and consider their financial situation before making decisions [1]. Group 2 - The website includes information about complex financial instruments such as cryptocurrencies and contracts for difference (CFDs), which carry a high risk of losing money [1]. - It encourages users to understand how these instruments work and the associated risks before investing [1].